Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
A vaccination regimen involving the co-administration of pneumococcal and hepatitis B vaccines, typically indicated for high-risk individuals such as patients with chronic kidney disease (CKD) or those initiating hemodialysis. The pneumococcal component (which may include conjugate vaccines like PCV13/15/20 or polysaccharide vaccines like PPSV23) targets capsular antigens of Streptococcus pneumoniae to prevent pneumonia and invasive pneumococcal disease. The hepatitis B component consists of recombinant hepatitis B surface antigen (HBsAg) to induce immunity against the hepatitis B virus (HBV). In hemodialysis populations, these vaccines are critical for reducing infection-related morbidity and mortality, although patients often exhibit lower seroconversion rates and may require higher doses or accelerated schedules compared to the general population.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on pneumococcal vaccine + hepatitis B vaccine.